Investor Spotlight: AmorChem
JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1
September 27, 2018 from 12:30 PM to 15:00 PM (EDT)
$10 - $35
Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.
On September 27th, Elizabeth Douville, Inès Holzbaur, and Maxime Ranger from AmorChem will present an overview of the firm, its investment strategy, its primary areas of interest, and a few investment case studies. Following the presentation, they will meet 1-on-1 with companies, university researchers or tech transfer offices that have been accepted after applying online.
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due September 7th, 2018. Apply Here.
Located in Montreal, AmorChem is an early-stage venture capital fund focused on creating promising life science companies from therapeutic research programs originating primarily from universities and research centers. The AmorChem fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialization of its therapeutic programs. AmorChem’s business model involves financing the earlier-stage research programs within the academic labs and spinning off companies to enable reaching human proof-of-concept in syndication with other venture funds. Launched in 2011, the first fund built a portfolio of 24 technologies, leading to two successfully-transacted pharma exits and the creation of six spin-out companies (Mperia Therapeutics, Corbin Therapeutics, SpecificiT Pharma, SemaThera, Eosinate, and Mucotek).
The attractiveness of the AmorChem fund model and the role it plays in starting up companies in the biotech ecosystem were highlighted in September 2017 with the launch of the AmorChem II Fund. With the goal of expanding its reach into universities and research centers in Ontario, AmorChem is seeking innovative research programs in different therapeutic areas including oncology, inflammation, infectious diseases and neurodegenerative diseases.
To be considered for a 1-on-1 meeting complete the information required here. Applications due by September 7th, 2018.
Elizabeth Douville, Ph.D. | Founder and Managing Partner, AmorChem read bio »
Inès Holzbaur, Ph.D. | Founder and Managing Partner, AmorChem read bio »
Maxime Ranger, Ph.D. MBA | General Partner, AmorChem read bio »
10:30AM | Registration and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
1:00-5:00 PM | One-on-One Meetings*
*Companies, researchers or tech transfer offices must have applied for a one-on-one meeting ahead of time and been approved. Applications are due September 7, 2018. Apply Here.
$15 | Presentation & Lunch
$25 | At the door - Presentation & Lunch Only
JLABS @ Toronto
661 University Ave, Suite 1300
Elizabeth Douville, Ph.D. | Founder and Managing Partner, AmorChem
Dre. Elizabeth Douville is a founder and managing partner at AmorChem. Dre. Douville brings to AmorChem a deep and long-standing experience in venture capital investing having been General Partner of GeneChem, a leading North American life sciences venture capital fund manager. She joined GeneChem in 1997, moving rapidly from manager to partner with the different funds under management. She was an active board member for many Canadian and American portfolio companies where she contributed to their development and exit strategies. Elizabeth currently sits on the boards of the following not-for-profit entities: BioQuébec, Genome Canada and BioCanRx, and is a member of CFI. She also sits on the board of the following AmorChem I spin-off companies: Mperia Therapeutics, Corbin Therapeutics, SemaThera and Eosinate. Dre. Douville trained as a biochemist, obtaining her Ph.D. from the University of Ottawa and a post-doctoral fellow from the Imperial Cancer Research Fund in London, UK. She also has a business degree from CIREM/HEC.
^ Back to speakers' list ^
Inès Holzbaur, Ph.D. | Founder and Managing Partner, AmorChem
Dre. Inès Holzbaur is a founder and managing partner at AmorChem. In 2011, she participated in the origination and establishment of AmorChem’s disruptive model for financing very early-stage drug development projects. As part of the fund’s activities, she led the closing of a strategic alliance with the pharmaceutical company Roche and the sale of a portfolio asset to Vertex Pharmaceuticals. She is also the chairman of the board of NuChem Therapeutics Inc., a medicinal chemistry CRO founded by AmorChem. She began her career in 1999 as a manager and then vice-president of the GeneChem and AgeChem venture capital funds. During this period, she financed several companies in Canada, the US and Europe. As a result, she has held positions on the board of a number of companies, most notably a pioneer in the field of immuno-oncology, BioVex Inc., which was sold to Amgen for $1B. In addition to her fund management activities, she is a member of the board of directors of Réseau Capital, the Québec Venture Capital and Private Equity Association, and of the CQIB Québec Life Sciences Incubator. She received a bachelor’s degree in chemistry from Concordia University and a Ph.D. in chemistry from Cambridge University in the UK.
^ Back to speakers' list ^
Maxime Ranger, Ph.D. MBA | General Partner, AmorChem
Dr Maxime Ranger is General Partner at AmorChem. He is CEO of Mperia Therapeutics and Director of the Board of portfolio companies, such as SemaThera and Corbin Therapeutics. Dr Ranger founded and managed a series of startup companies within Quebec’s ecosystem: Inversago Pharma (2015-present), gIcare pharma (2011-2015) with more than 10M$ raised in venture capital and GInova Pharma (2008-2011). Previously, he held management positions at Labopharm (2001-2003, acquired by Paladin, became Endo), Bioxalis Medica (2003-2004, acquired by Procyon, became Ambrillia) and Ecopia Bioscience (2004-2008, became Thallion, acquired by Bellus Health). Mr. Ranger has completed an Executive MBA at UQAM and Université Paris-Dauphine (2012), performed a postdoctoral fellow at Stanford University (2001) and holds a Ph.D. in chemistry, Material Sciences, from Laval University (2000).
^ Back to speakers' list ^